Your browser is no longer supported. Please, upgrade your browser.
Molecular Partners AG
Index- P/E- EPS (ttm)-2.43 Insider Own- Shs Outstand32.28M Perf Week-8.75%
Market Cap872.04M Forward P/E17.26 EPS next Y1.59 Insider Trans- Shs Float24.99M Perf Month34.33%
Income- PEG- EPS next Q-1.83 Inst Own4.80% Short Float0.05% Perf Quarter45.90%
Sales9.49M P/S91.84 EPS this Y-48.10% Inst Trans1.60% Short Ratio0.20 Perf Half Y34.51%
Book/sh4.21 P/B6.52 EPS next Y255.90% ROA- Target Price39.39 Perf Year-
Cash/sh5.30 P/C5.18 EPS next 5Y- ROE- 52W Range9.57 - 32.04 Perf YTD43.07%
Dividend- P/FCF- EPS past 5Y- ROI-50.90% 52W High-14.36% Beta-
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low186.73% ATR2.02
Employees158 Current Ratio4.20 Sales Q/Q-48.50% Oper. Margin- RSI (14)58.50 Volatility3.90% 6.05%
OptionableNo Debt/Eq0.05 EPS Q/Q65.20% Profit Margin- Rel Volume0.41 Prev Close27.96
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume59.06K Price27.44
Recom2.00 SMA2012.17% SMA5046.70% SMA20043.42% Volume24,129 Change-1.86%
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Jan-28-22 05:57AM  
Jan-23-22 02:28AM  
Jan-18-22 01:00AM  
Jan-13-22 05:00PM  
Jan-12-22 10:13AM  
Jan-11-22 11:37AM  
Jan-10-22 06:51PM  
Jan-06-22 10:00AM  
Jan-05-22 04:05PM  
Dec-15-21 01:00AM  
Dec-14-21 12:16PM  
Dec-12-21 04:00PM  
Dec-09-21 01:00AM  
Dec-06-21 01:00AM  
Dec-03-21 01:00AM  
Nov-30-21 12:48PM  
Nov-24-21 01:00AM  
Nov-16-21 06:49AM  
Nov-04-21 02:00AM  
Oct-28-21 01:00AM  
Oct-20-21 01:00AM  
Sep-03-21 04:05PM  
Aug-26-21 01:00AM  
Aug-09-21 01:00AM  
Jul-13-21 06:55AM  
Jul-08-21 09:04AM  
Jun-15-21 10:00PM  
Jun-13-21 04:00PM  
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.